Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal versus submacular injection of rtPA for acute submacular haemorrhages
2010-023636-17Phase 2Completed
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of tissue-plasminogen activator in submacular hemorrhage (SMH) (2 arms), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoint: Location of haemorrhage at baseline and 3 months. Started Nov 2010; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
submacular hemorrhage (SMH)
Beyond the preview
Go deeper on 2010-023636-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023636-17.